Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al. -
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCIYang A, Pon Q, Dehghani P et al.
-
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.Lee CW, Ahn JM, Park SJ et al.
-
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionS-J Lee, JY Cho, TICO Investigators et al.
-
A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor SignalingBAT Rodriguez, A Bhan, A Beswick et al.
-
Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical TrialR Mehran, J Chandrasekhar, P Urban et al.
-
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialDewilde WJ, Oirbans T, WOEST study investigators.
-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
